Drugs / Kurmoxilil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07857226 | Sep 2026 → Jun 2028 expected | breast cancer | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kurmoxilil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07857226 ↗ |
| Route | Oral | “Kurmoxilil will be administered orally” NCT07857226 ↗ |